Evidence of neuroinflammation and immunotherapy responsiveness in individuals with down syndrome regression disorder
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1866-1955
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Evidence of neuroinflammation and immunotherapy responsiveness in individuals with down syndrome regression disorder ; volume:14 ; number:1 ; day:3 ; month:6 ; year:2022 ; pages:1-14 ; date:12.2022
Journal of neurodevelopmental disorders ; 14, Heft 1 (3.6.2022), 1-14, 12.2022
- Creator
-
Santoro, Jonathan D.
Partridge, Rebecca
Tanna, Runi
Pagarkar, Dania
Khoshnood, Mellad
Rehmani, Mustafa
Kammeyer, Ryan M.
Gombolay, Grace Y.
Fisher, Kristen
Conravey, Allison
El-Dahr, Jane
Christy, Alison L.
Patel, Lina
Manning, Melanie A.
Mater, Heather Van
Rafii, Michael S.
Quinn, Eileen A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s11689-022-09446-w
- URN
-
urn:nbn:de:101:1-2022080221212024907669
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Santoro, Jonathan D.
- Partridge, Rebecca
- Tanna, Runi
- Pagarkar, Dania
- Khoshnood, Mellad
- Rehmani, Mustafa
- Kammeyer, Ryan M.
- Gombolay, Grace Y.
- Fisher, Kristen
- Conravey, Allison
- El-Dahr, Jane
- Christy, Alison L.
- Patel, Lina
- Manning, Melanie A.
- Mater, Heather Van
- Rafii, Michael S.
- Quinn, Eileen A.
- SpringerLink (Online service)
Other Objects (12)
Immunotherapy responsiveness and risk of relapse in Down syndrome regression disorder
Diagnostic abnormalities, disease severity and immunotherapy responsiveness in individuals with Down syndrome regression disorder
Down’s syndrome, neuroinflammation, and Alzheimer neuropathogenesis
Altered endotoxin responsiveness in healthy children with Down syndrome
BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy
Predictive biomarkers for the responsiveness of recurrent glioblastomas to activated killer cell immunotherapy
Immunotherapy targeting the PD-1 pathway alleviates neuroinflammation caused by chronic Toxoplasma infection
Synthetic immunity to break down the bottleneck of cancer immunotherapy
Down Down Down
Down Down Down
Down-regulation of MKP-1 in hippocampus protects against stress-induced depression-like behaviors and neuroinflammation
Neuroinflammation: 2021 update
Immunotherapy responsiveness and risk of relapse in Down syndrome regression disorder
Diagnostic abnormalities, disease severity and immunotherapy responsiveness in individuals with Down syndrome regression disorder
Down’s syndrome, neuroinflammation, and Alzheimer neuropathogenesis
Altered endotoxin responsiveness in healthy children with Down syndrome
BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy
Predictive biomarkers for the responsiveness of recurrent glioblastomas to activated killer cell immunotherapy
Immunotherapy targeting the PD-1 pathway alleviates neuroinflammation caused by chronic Toxoplasma infection
Synthetic immunity to break down the bottleneck of cancer immunotherapy
Down Down Down
Down Down Down
Down-regulation of MKP-1 in hippocampus protects against stress-induced depression-like behaviors and neuroinflammation
Neuroinflammation: 2021 update
Immunotherapy responsiveness and risk of relapse in Down syndrome regression disorder
Diagnostic abnormalities, disease severity and immunotherapy responsiveness in individuals with Down syndrome regression disorder
Down’s syndrome, neuroinflammation, and Alzheimer neuropathogenesis
Altered endotoxin responsiveness in healthy children with Down syndrome
BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy
Predictive biomarkers for the responsiveness of recurrent glioblastomas to activated killer cell immunotherapy
Immunotherapy targeting the PD-1 pathway alleviates neuroinflammation caused by chronic Toxoplasma infection
Synthetic immunity to break down the bottleneck of cancer immunotherapy
Down Down Down
Down Down Down
Down-regulation of MKP-1 in hippocampus protects against stress-induced depression-like behaviors and neuroinflammation